|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Jonathan_Montagu
|
|
gptkbp:developedBy
|
small molecule therapeutics
|
|
gptkbp:focusesOn
|
allosteric drug discovery
|
|
gptkbp:foundedYear
|
2017
|
|
gptkbp:founder
|
gptkb:Gerard_Blanchard
gptkb:Jonathan_Montagu
|
|
gptkbp:headquartersLocation
|
gptkb:Boston,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
HotSpot Therapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:investor
|
gptkb:RA_Capital_Management
gptkb:Tavistock_Life_Sciences
gptkb:Pfizer_Ventures
gptkb:SR_One
gptkb:Cambridge_Innovation_Capital
gptkb:Morningside_Ventures
gptkb:Atlas_Venture
gptkb:Ascension_Ventures
gptkb:Sofinnova_Partners
|
|
gptkbp:mission
|
to discover and develop allosteric medicines for serious diseases
|
|
gptkbp:numberOfEmployees
|
51-200
|
|
gptkbp:platform
|
gptkb:SpotFinder
|
|
gptkbp:program
|
gptkb:HST-003
HST-004
HST-1011
|
|
gptkbp:seriesA
|
$45 million
|
|
gptkbp:seriesB
|
$65 million
|
|
gptkbp:seriesC
|
$100 million
|
|
gptkbp:target
|
gptkb:S6K
gptkb:IRF5
gptkb:PKC-theta
gptkb:CBP/p300
|
|
gptkbp:therapeuticArea
|
immunology
oncology
|
|
gptkbp:uses
|
computational biology
structure-based drug design
chemoproteomics
|
|
gptkbp:website
|
https://www.hotspotthera.com/
|
|
gptkbp:bfsParent
|
gptkb:David_Grayzel
|
|
gptkbp:bfsLayer
|
6
|